

# Zoltan Szekanecz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6125540/publications.pdf>

Version: 2024-02-01

240  
papers

12,620  
citations

25034

57  
h-index

29157

104  
g-index

254  
all docs

254  
docs citations

254  
times ranked

13431  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 325-331.	0.9	1,157
2	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.9	918
3	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
4	Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1155-1157.	0.9	383
5	Macrophages and their products in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 289-295.	4.3	275
6	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
7	Genetics of Rheumatoid Arthritis – A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 170-179.	6.5	244
8	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. <i>Rheumatology</i> , 2014, 53, 2143-2154.	1.9	239
9	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
10	Novel Biomarkers in Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 385-400.	3.8	204
11	Mechanisms of Disease: angiogenesis in inflammatory diseases. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 635-643.	3.2	178
12	In situ Expression of Cytokines and Cellular Adhesion Molecules in the Skin of Patients with Systemic Sclerosis. <i>Pathobiology</i> , 1993, 61, 239-246.	3.8	166
13	Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010, 9, 140-143.	5.8	160
14	Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1266-1277.	6.7	156
15	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	8.0	154
16	Vascular involvement in rheumatic diseases: 'vascular rheumatology'. <i>Arthritis Research and Therapy</i> , 2008, 10, 224.	3.5	144
17	Differential Distribution of Intercellular Adhesion Molecules (ICAM-1, ICAM-2, and ICAM-3) and THE MS-1 Antigen in Normal and Diseased Human Synovia. <i>Arthritis and Rheumatism</i> , 1994, 37, 221-231.	6.7	138
18	Chemokines and angiogenesis. <i>Current Opinion in Rheumatology</i> , 2001, 13, 202-208.	4.3	135

#	ARTICLE	IF	CITATIONS
19	Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. <i>Journal of Rheumatology</i> , 2008, 35, 398-406.	2.0	130
20	Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 5-13.	8.0	129
21	Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: The possible role for IL-6 and interferon-gamma in vascular inflammation. <i>Agents and Actions</i> , 1994, 42, 159-162.	0.7	128
22	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
23	Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 248-250.	0.9	122
24	Angiogenesis and vasculogenesis in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 299-306.	4.3	122
25	Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 10, 490-494.	5.8	122
26	Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. <i>Rheumatology</i> , 2007, 46, 759-762.	1.9	119
27	Validated methods for assessment of subclinical atherosclerosis in rheumatology. <i>Nature Reviews Rheumatology</i> , 2012, 8, 224-234.	8.0	118
28	TLRs, future potential therapeutic targets for RA. <i>Autoimmunity Reviews</i> , 2017, 16, 103-113.	5.8	118
29	Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 705-710.	2.2	115
30	Chemokines and chemokine receptors in arthritis. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 153-167.	2.1	111
31	Targeting Cannabinoid Signaling in the Immune System: Highly Exciting Questions, Possibilities, and Challenges. <i>Frontiers in Immunology</i> , 2017, 8, 1487.	4.8	111
32	Angiogenesis in rheumatoid arthritis. <i>Autoimmunity</i> , 2009, 42, 563-573.	2.6	106
33	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
34	Survival and causes of death in 366 Hungarian patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 59-63.	0.9	101
35	Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. <i>BMC Medical Genomics</i> , 2010, 3, 15.	1.5	100
36	Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 585-595.	8.0	99

#	ARTICLE	IF	CITATIONS
37	Cardiac manifestations in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2007, 6, 379-386.	5.8	98
38	Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. <i>Autoimmunity Reviews</i> , 2011, 10, 416-425.	5.8	98
39	Assessment of Subclinical Vascular Disease Associated with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 723-729.	2.0	96
40	Angiogenesis and its targeting in rheumatoid arthritis. <i>Vascular Pharmacology</i> , 2009, 51, 1-7.	2.1	95
41	Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 349-358.	3.8	94
42	Targeting of proangiogenic signalling pathways in chronic inflammation. <i>Nature Reviews Rheumatology</i> , 2016, 12, 111-122.	8.0	93
43	A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2009, 28, 655-662.	2.2	91
44	Chemokines in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1998, 20, 115-132.	4.0	87
45	B-cells and their targeting in rheumatoid arthritis – Current concepts and future perspectives. <i>Autoimmunity Reviews</i> , 2011, 11, 28-34.	5.8	85
46	Clinical Course, Prognosis, and Causes of Death in Mixed Connective Tissue Disease. <i>Journal of Rheumatology</i> , 2013, 40, 1134-1142.	2.0	85
47	New insights in synovial angiogenesis. <i>Joint Bone Spine</i> , 2010, 77, 13-19.	1.6	84
48	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.9	83
49	Interleukin-8 and Tumor Necrosis Factor-Alpha Are Involved in Human Aortic Endothelial Cell Migration. <i>Pathobiology</i> , 1994, 62, 134-139.	3.8	75
50	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
51	Vascular endothelium and immune responses: implications for inflammation and angiogenesis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 97-114.	1.9	71
52	Increased Synovial Expression of Transforming Growth Factor (TGF)- $\beta$ 2 Receptor Endoglin and TGF- $\beta$ 1 in Rheumatoid Arthritis: Possible Interactions in the Pathogenesis of the Disease. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 187-194.	2.0	70
53	Vascular effects of biologic agents in RA and spondyloarthropathies. <i>Nature Reviews Rheumatology</i> , 2009, 5, 677-684.	8.0	70
54	Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 95.	3.5	70

#	ARTICLE	IF	CITATIONS
55	Cytokines in Rheumatoid Arthritis. <i>Drugs and Aging</i> , 1998, 12, 377-390.	2.7	65
56	Antiphospholipid antibodies in acute coronary syndrome. <i>Lupus</i> , 2004, 13, 423-427.	1.6	65
57	Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 26-31.	6.5	65
58	Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 521-529.	1.6	65
59	The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. <i>Archives of Biochemistry and Biophysics</i> , 2019, 670, 82-93.	3.0	60
60	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 925-936.	0.9	59
61	Malignancies and soluble tumor antigens in rheumatic diseases. <i>Autoimmunity Reviews</i> , 2006, 6, 42-47.	5.8	58
62	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	8.0	57
63	Cellular adhesion molecules in rat adjuvant arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 810-819.	6.7	56
64	Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by cytokine-activated human aortic endothelial cells: a possible role for ICAM-1 and sICAM-1 in atherosclerotic aortic aneurysms. <i>Clinical and Experimental Immunology</i> , 2008, 98, 337-343.	2.6	53
65	Prolactin and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 189-198.	6.5	52
66	Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1658-63.	2.0	52
67	Malignancies in Autoimmune Rheumatic Diseases – A Mini-Review. <i>Gerontology</i> , 2011, 57, 3-10.	2.8	51
68	Of mice and men: how animal models advance our understanding of T-cell function in RA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 160-170.	8.0	50
69	Effects of 1-year anti-TNF- $\alpha$ therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020, 39, 167-175.	2.2	50
70	Update on synovitis. <i>Current Rheumatology Reports</i> , 2001, 3, 53-63.	4.7	47
71	Effects of targeted therapies on the bone in arthritides. <i>Autoimmunity Reviews</i> , 2017, 16, 313-320.	5.8	47
72	Cell-cell interactions in synovitis. Endothelial cells and immune cell migration. <i>Arthritis Research</i> , 2000, 2, 368.	2.0	45

#	ARTICLE	IF	CITATIONS
73	Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis. <i>Rheumatology International</i> , 2006, 26, 964-971.	3.0	45
74	Association of ARTS1 Gene Polymorphisms with Ankylosing Spondylitis in the Hungarian Population: The rs27044 Variant Is Associated with HLA-B*2705 Subtype in Hungarian Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 379-384.	2.0	45
75	Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 281.	1.9	45
76	Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do. <i>Autoimmunity Reviews</i> , 2016, 15, 756-769.	5.8	45
77	Malignancies associated with systemic sclerosis. <i>Autoimmunity Reviews</i> , 2012, 11, 852-855.	5.8	43
78	Impact of obesity on autoimmune arthritis and its cardiovascular complications. <i>Autoimmunity Reviews</i> , 2018, 17, 821-835.	5.8	42
79	Effects of 1-year anti-TNF- $\alpha$ therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. <i>Rheumatology International</i> , 2020, 40, 427-436.	3.0	42
80	Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. <i>Journal of Rheumatology</i> , 2008, 35, 1329-33.	2.0	42
81	Transmembrane TNF- $\alpha$ Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF- $\beta$ : Therapeutic Implications. <i>Journal of Immunology</i> , 2016, 196, 1146-1157.	0.8	40
82	Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. <i>Journal of Investigative Medicine</i> , 1998, 46, 27-41.	1.6	40
83	Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis: Potential Adhesion Molecules in Synovial Inflammation?. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 359-371.	3.8	39
84	Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immunocomplex production in patients with systemic sclerosis - a prospective case-series study. <i>Arthritis Research and Therapy</i> , 2013, 15, R105.	3.5	39
85	Common mechanisms and holistic care in atherosclerosis and osteoporosis. <i>Arthritis Research and Therapy</i> , 2019, 21, 15.	3.5	39
86	Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices. <i>Journal of Autoimmunity</i> , 2008, 31, 372-376.	6.5	38
87	Effects of Biologics on Vascular Function and Atherosclerosis Associated with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 814-821.	3.8	38
88	Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. <i>Genome Medicine</i> , 2013, 5, 59.	8.2	38
89	Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 253-60.	0.8	37
90	Increased Synovial Expression of the Adhesion Molecules CD66a, CD66b, and CD31 in Rheumatoid and Osteoarthritis. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 180-186.	2.0	34

#	ARTICLE	IF	CITATIONS
91	Endothelial Cells in Inflammation and Angiogenesis. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 319-323.	3.1	34
92	Suppression of Proteoglycan-Induced Autoimmune Arthritis by Myeloid-Derived Suppressor Cells Generated In Vitro from Murine Bone Marrow. <i>PLoS ONE</i> , 2014, 9, e111815.	2.5	34
93	Ferritin and prolactin levels in multiple sclerosis. <i>Israel Medical Association Journal</i> , 2011, 13, 91-5.	0.1	34
94	Effects of Thrombospondin-1 on Disease Course and Angiogenesis in Rat Adjuvant-Induced Arthritis. <i>Clinical Immunology and Immunopathology</i> , 1998, 86, 199-208.	2.0	33
95	Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. <i>Immunologic Research</i> , 2013, 56, 439-443.	2.9	33
96	Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 409-15.	0.8	33
97	Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. <i>Joint Bone Spine</i> , 2016, 83, 675-679.	1.6	32
98	Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. <i>Netherlands Journal of Medicine</i> , 2011, 69, 356-66.	0.5	32
99	Biologics "beyond the joints". <i>Autoimmunity Reviews</i> , 2010, 9, 820-824.	5.8	31
100	Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. <i>Lupus</i> , 2011, 20, 730-735.	1.6	31
101	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. <i>Rheumatology</i> , 2022, 61, 1783-1794.	1.9	31
102	Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2011, 13, 147-52.	0.1	31
103	Lymphocyte adhesion to high endothelium is mediated by two $\alpha 1$ integrin receptors for fibronectin, $\alpha 4 \beta 1$ and $\alpha 5 \beta 1$ . <i>Journal of Cell Science</i> , 1992, 101, 885-894.	2.0	30
104	Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy program in ankylosing spondylitis. <i>Rheumatology International</i> , 2012, 32, 3931-3936.	3.0	29
105	Perspectives of pharmacological treatment in otosclerosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 793-804.	1.6	29
106	Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. <i>Journal of Investigative Medicine</i> , 1996, 44, 124-35.	1.6	29
107	Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects. <i>Rheumatology International</i> , 2009, 29, 793-796.	3.0	28
108	New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. <i>Rheumatology</i> , 2010, 49, 25-33.	1.9	28

#	ARTICLE	IF	CITATIONS
109	Cognitive dysfunction in autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2020, 22, 78.	3.5	28
110	Targeting Angiogenesis in Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2008, 4, 298-303.	0.8	27
111	Plasma Homocysteine Levels, The Prevalence of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Macrovascular Disorders in Systemic Sclerosis: Risk Factors for Accelerated Macrovascular Damage?. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 145-149.	6.5	27
112	Longterm Effects of Rituximab on B Cell Counts and Autoantibody Production in Rheumatoid Arthritis: Use of High-sensitivity Flow Cytometry for More Sensitive Assessment of B Cell Depletion. <i>Journal of Rheumatology</i> , 2013, 40, 565-571.	2.0	26
113	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	2.8	26
114	Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. <i>Osteoporosis International</i> , 2021, 32, 1621-1629.	3.1	26
115	Peripheral Blood Gene Expression and IgG Glycosylation Profiles as Markers of Tocilizumab Treatment in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 916-928.	2.0	25
116	Pneumococcal vaccination in autoimmune rheumatic diseases. <i>RMD Open</i> , 2017, 3, e000484.	3.8	25
117	Development of temporomandibular joint arthritis: The use of animal models. <i>Joint Bone Spine</i> , 2017, 84, 145-151.	1.6	24
118	Anti-mutated citrullinated vimentin (anti-MCV) and anti-65kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2012, 79, 63-66.	1.6	23
119	Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 249-257.	8.0	23
120	Lupus and Cardiovascular Disease: The Facts. <i>Lupus</i> , 2006, 15, 3-10.	1.6	22
121	Pharmacogenetics and pharmacogenomics in rheumatology. <i>Immunologic Research</i> , 2013, 56, 325-333.	2.9	22
122	Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2008, 10, 32-6.	0.1	22
123	Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2008, 27, 1163-1166.	2.2	21
124	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.9	21
125	Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001032.	3.8	21
126	A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 81-89.	1.8	21



#	ARTICLE	IF	CITATIONS
127	Pro-inflammatory cytokines in atherosclerosis. Israel Medical Association Journal, 2008, 10, 529-30.	0.1	21
128	Catastrophic antiphospholipid syndrome in cancer. Haematologia, 2000, 30, 303-311.	0.3	20
129	Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis. Mediators of Inflammation, 2015, 2015, 1-4.	3.0	20
130	Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. Rheumatology International, 2017, 37, 1835-1845.	3.0	20
131	Effect of FcÎ³-receptor 3a ( <i>FCGR3A</i> ) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. RMD Open, 2017, 3, e000485.	3.8	20
132	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 537-549.	1.4	19
133	Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. Rheumatology International, 2020, 40, 529-540.	3.0	19
134	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Frontiers in Immunology, 2022, 13, 846248.	4.8	19
135	Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus, 2018, 27, 1552-1558.	1.6	18
136	Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.. Journal of Clinical Pathology, 1997, 50, 314-319.	2.0	17
137	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. RMD Open, 2018, 4, e000756.	3.8	17
138	EULAR â€œpoints to considerâ€™ for the conduction of workforce requirement studies in rheumatology. RMD Open, 2018, 4, e000780.	3.8	16
139	Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. Clinical Rheumatology, 2014, 33, 623-629.	2.2	15
140	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 139-147.	1.9	15
141	Biologics, cardiovascular effects and cancer. BMC Medicine, 2014, 12, 48.	5.5	14
142	Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis. Immunologic Research, 2016, 64, 619-626.	2.9	14
143	Treatment of ankylosing spondylitis with biologics and targeted physical therapy. Zeitschrift Fur Rheumatologie, 2013, 72, 997-1004.	1.0	13
144	Characterization and Localization of Citrullinated Proteoglycan Aggrecan in Human Articular Cartilage. PLoS ONE, 2016, 11, e0150784.	2.5	13

#	ARTICLE	IF	CITATIONS
145	Editorial: Comorbidity Burden in Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 197.	2.6	13
146	The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102421.	5.8	13
147	Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: Rituximab may be the right choice?. <i>Autoimmunity</i> , 2012, 45, 304-309.	2.6	12
148	Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. <i>Rheumatology</i> , 2014, 53, 2035-2043.	1.9	12
149	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	2.8	12
150	Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF treatment responders in inflammatory diseases. <i>Electrophoresis</i> , 2015, 36, 1330-1335.	2.4	12
151	Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis. <i>Current Immunology Reviews</i> , 2016, 12, 35-46.	1.2	12
152	Corneal Manifestations of Systemic Sclerosis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 968-977.	1.8	12
153	HLA-DR genotypes in familial rheumatoid arthritis: increased frequency of protective and neutral alleles in a multicase family. <i>Journal of Rheumatology</i> , 2005, 32, 2299-302.	2.0	12
154	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e13.	3.9	12
155	Ex Vivo Soft-Laser Treatment Inhibits the Synovial Expression of Vimentin and $\alpha$ -Enolase, Potential Autoantigens in Rheumatoid Arthritis. <i>Physical Therapy</i> , 2011, 91, 665-674.	2.4	11
156	Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls. <i>Osteoporosis International</i> , 2017, 28, 1271-1277.	3.1	11
157	Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 213.	3.5	11
158	Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 274.	3.5	11
159	Salivary citrullinated proteins in rheumatoid arthritis and associated periodontal disease. <i>Scientific Reports</i> , 2021, 11, 13525.	3.3	11
160	Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. <i>Biomolecules</i> , 2021, 11, 1535.	4.0	11
161	Non-MHC Risk Alleles in Rheumatoid Arthritis and in the Syntenic Chromosome Regions of Corresponding Animal Models. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	10
162	Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status. <i>RMD Open</i> , 2021, 7, e001804.	3.8	10

#	ARTICLE	IF	CITATIONS
163	Occurrence of pulmonary rheumatoid nodules following biological therapies. <i>Clinical Rheumatology</i> , 2015, 34, 1639-1642.	2.2	9
164	Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102658.	5.8	9
165	Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001765.	2.8	9
166	Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 94.	3.5	8
167	Assessment of cervical spine involvement in rheumatoid arthritis patients in the era of biologics: a real-life, cross-sectional MRI study. <i>Rheumatology International</i> , 2020, 40, 915-921.	3.0	8
168	Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases. <i>Agents and Actions</i> , 1991, 33, 254-259.	0.7	7
169	Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: Data from the first Central-Eastern European cohort. <i>Joint Bone Spine</i> , 2011, 78, 652-653.	1.6	7
170	Atherosclerosis in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2012, 2012, 1-2.	3.0	7
171	In Vivo Calcium and Phosphate Iontophoresis for the Topical Treatment of Osteoporosis. <i>Physical Therapy</i> , 2012, 92, 289-297.	2.4	7
172	Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. <i>Clinical Immunology</i> , 2019, 199, 47-51.	3.2	7
173	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	2.9	7
174	A prospective, longitudinal monocentric study on laser Doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis. <i>Rheumatology International</i> , 2020, 40, 415-424.	3.0	7
175	Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. <i>Frontiers in Oncology</i> , 2021, 11, 725465.	2.8	7
176	Lymphocyte adhesion to high endothelium is mediated by two beta 1 integrin receptors for fibronectin, alpha 4 beta 1 and alpha 5 beta 1. <i>Journal of Cell Science</i> , 1992, 101 ( Pt 4), 885-94.	2.0	7
177	Effects of Classical Breathing Exercises on Posture, Spinal and Chest Mobility among Female University Students Compared to Currently Popular Training Programs. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3728.	2.6	7
178	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
179	Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: Computer-aided versus conventional microscopic evaluation of routine diagnostic samples from patients with vasculitis or other inflammatory diseases. <i>Clinica Chimica Acta</i> , 2020, 511, 117-124.	1.1	6
180	Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case-control study. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 70.	1.9	6

#	ARTICLE	IF	CITATIONS
181	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	2.2	6
182	Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of 1-year Antitumor Necrosis Factor- $\alpha$ Therapy. <i>Journal of Rheumatology</i> , 2021, 48, 821-828.	2.0	5
183	Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients. <i>Frontiers in Medicine</i> , 2021, 8, 785744.	2.6	5
184	Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2). <i>RMD Open</i> , 2022, 8, e002024.	3.8	5
185	Tocilizumab Treatment in Polyarteritis Nodosa. <i>Israel Medical Association Journal</i> , 2019, 21, 560-562.	0.1	5
186	Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 797-806.	3.0	4
187	Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
188	Development of natural calcium- and phosphate-donating microparticles and a new iontophoretic apparatus for the topical treatment of local osteoporosis. Preliminary in vitro and in vivo studies. <i>Joint Bone Spine</i> , 2010, 77, 426-431.	1.6	3
189	Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196.	3.5	3
190	Associations of vascular and bone status in arthritis patients. <i>Scientific Reports</i> , 2021, 11, 19504.	3.3	3
191	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 817.	1.9	3
192	Effects of one-year anti-TNF- $\alpha$ therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides. <i>Rheumatology and Orthopedic Medicine</i> , 2019, 4, .	0.2	3
193	Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1083-1090.	1.6	2
194	Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?. <i>Clinical Rheumatology</i> , 2018, 37, 1183-1188.	2.2	2
195	Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 572-578.	2.0	2
196	Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 325.	1.9	2
197	Cell Recruitment and Angiogenesis. , 2013, , 358-368.e5.		2
198	The effects of breathing exercises in comparison with other exercise programs on cardiorespiratory fitness among healthy female college students. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 62-68.	0.7	2

#	ARTICLE	IF	CITATIONS
199	Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 839374.	4.1	2
200	Reflections on a contemporary European tragedy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 747-748.	0.9	2
201	SAT0190...Long-Term Follow-Up of 280 Patients with Mixed Connective Tissue Disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A645.2-A645.	0.9	1
202	A7.20...Response to Infliximab Therapy can be Predicted using Distinct, Non-Overlapping Gene Panels of Peripheral Blood Gene Expression in Rheumatoid Arthritis and Crohn's Disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A55.1-A55.	0.9	1
203	AB0606...Effects of 12-month etanercept or certolizumab pegol therapy on disease activity, bone turnover markers and peripheral qct bone mineral density in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A975.2-A975.	0.9	1
204	THU0399...Effects of 12-Month Etanercept Therapy on Disease Activity, Bone Turnover Markers and Peripheral QCT Bone Mineral Density in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A300.2-A300.	0.9	1
205	FRI0144...Analysis of the Association Between Cigarette Smoking and Clinical Response to Certolizumab Pegol Treatment in Hungarian Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 474.1-474.	0.9	1
206	AB0312...Predictors of Disease Course after The Discontinuation of Biologic Therapy in Rheumatoid Arthritis Patients with Long-Term Remission. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1007.1-1007.	0.9	1
207	Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 340-341.	1.1	1
208	OP0074...A FRAMEWORK OF POTENTIAL INTERVENTIONS TO ACCELERATE GENDER-EQUITABLE CAREER ADVANCEMENT IN ACADEMIC RHEUMATOLOGY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 39.1-40.	0.9	1
209	POS0383...EFFECTS OF TOFACITINIB THERAPY ON ARGININE AND METHIONINE METABOLITES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS: A METABOLOMIC APPROACH. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 421.2-422.	0.9	1
210	Anti-Inflammatory Therapeutic Approaches. , 2012, , 513-528.		1
211	Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1010-1018.	0.8	1
212	Successful Treatment of Rheumatoid Arthritis-Associated Renal AA Amyloidosis with Tocilizumab. <i>Israel Medical Association Journal</i> , 2020, 22, 455-457.	0.1	1
213	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1056-1067.	0.8	1
214	Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.7	1
215	Actualit�s sur lâ€™angiogen�se synoviale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 14-20.	0.0	0
216	Combination of peripheral blood gene expression profiles and clinical parameters predicts response to tocilizumab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A13-A14.	0.9	0

#	ARTICLE	IF	CITATIONS
217	Associations entre lâ€™Ã©pitope partagÃ© de lâ€™HLA, les anticorps anti-peptide citrullinÃ© et les facteurs liÃ©s au mode de vie chez des patients hongrois atteints de polyarthrite rhumatoÃ©de: donnÃ©es de la premiÃ¨re cohorte de lâ€™Europe centrale et de lâ€™Est. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 93-94.	0.0	0
218	FRI0398â€¦Derailed b cell homeostasis in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 2013, 72, A508.1-A508.	0.9	0
219	Editorial paper Treatment strategies in rheumatoid arthritis. Reumatologia, 2013, 4, 239-248.	1.1	0
220	AB0042â€¦Natural Autoantibodies Against Citrate Synthase and DNA Topoisomerase I in Patients with Rheumatoid Arthritis and Spondyloarthritis Receiving Anti-TNF-Î± Therapy. Annals of the Rheumatic Diseases, 2015, 74, 904.1-904.	0.9	0
221	A8.13â€¦Natural autoantibodies against citrate synthase and DNA topoisomerase I in patients with rheumatoid arthritis and spondyloarthritis receiving anti-TNF-Î± therapy. Annals of the Rheumatic Diseases, 2015, 74, A86.2-A86.	0.9	0
222	OP0207â€¦Transmembrane TNF-Alpha Reverse Signaling Leading To TGF-Beta Production Is Selectively Activated by Anti-TNF-Alpha Targeting Molecules. Annals of the Rheumatic Diseases, 2016, 75, 135.1-135.	0.9	0
223	Cardiac Effects of Antirheumatic Drugs. Handbook of Systemic Autoimmune Diseases, 2017, 14, 489-529.	0.1	0
224	Ã‰valuation de lâ€™immunogÃ©nicitÃ© du vaccin pneumococcique conjuguÃ© 13-valent chez des patients atteints de polyarthrite rhumatoÃ©de traitÃ©s par Ã©tanercept. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 418-422.	0.0	0
225	THU0694â€¦Effects of ANTI-TNF therapy on soluble urokinase plasminogen activator receptor (SUPAR) levels in arthritis. , 2017, , .		0
226	AB0632â€¦Assessment of vegf and other cytokines in the tear of patients with systemic sclerosis. , 2017, , .		0
227	Cell Recruitment and Angiogenesis. , 2017, , 384-395.e5.		0
228	Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content. Lasers in Medical Science, 2018, 33, 1225-1236.	2.1	0
229	AB0840â€¦Determination of serum levels of and anti-drug antibody production against tnf inhibitors in ankylosing spondylitis: testing may be useful for the assessment of compliance but not that of treatment effectiveness. , 2018, , .		0
230	AB0689â€¦EVALUATION OF CARDIOVASCULAR DETERMINANTS OF DISEASE OUTCOME IN SYSTEMIC SCLEROSIS. , 2019, , .		0
231	Reply to: Comment on â€œeffects of 1-year anti-TNF-Î± therapy on vascular function in rheumatoid arthritis and ankylosing spondylitisâ€ by Cure et al.. Rheumatology International, 2020, 40, 509-509.	3.0	0
232	Biosimilars: To switch or not to switch â€œ that is the question. Reumatologia, 2020, 58, 1-3.	1.1	0
233	AB0160â€¦HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 1107.1-1107.	0.9	0
234	POS0222â€¦PREDICTORS OF RESPONSE: BASELINE CHARACTERISTICS AND EARLY TREATMENT RESPONSES ASSOCIATED WITH ACHIEVEMENT OF REMISSION AND LOW DISEASE ACTIVITY AMONG UPADACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 329.2-330.	0.9	0

#	ARTICLE	IF	CITATIONS
235	THU0010â€¦Vitamin d and oestrogen receptor polymorphism in rheumatoid arthritis. , 2001, , .		0
236	THU0196â€¦Disease Course after the Permanent Cessation of Biological Therapy in Inflammatory Rheumatic Diseases. Annals of the Rheumatic Diseases, 2013, 72, A230.1-A230.	0.9	0
237	Angiogenesis and vasculogenesis in rheumatoid arthritis. , 2015, , 764-767.		0
238	SAT0497â€¦Follow-up of disease activity in hungarian patients with idiopathic inflammatory myopathy. , 2018, , .		0
239	Posterior Reversible Encephalopathy Syndrome (PRES) Associated with Thrombotic Thrombocytopenic Purpura in a Systemic Lupus Erythematosus Patient. Israel Medical Association Journal, 2017, 19, 700-702.	0.1	0
240	The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients. Israel Medical Association Journal, 2018, 20, 217-221.	0.1	0